- Phase 2 trial evaluated BeiGene’s PD-1 inhibitor, Tevimbra, in operable esophageal cancer.
- Addition of Tevimbra before surgery led to higher pathological complete response rates.
- 44 patients in the Tevimbra group achieved a pathological complete response compared with 18.1% in the control group.
- At 1 year, 95.6% of patients who received Tevimbra remained alive without disease progression.
- The results may redefine the standard of care for treating operable esophagus tumors.
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
